** AbbVie ABBV.N forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug, that is now facing stiff competition
** Median PT of 29 brokerages covering the stock is $205.50 - LSEG data
ROBUST PIPELINE TO FUEL GROWTH
** J.P.Morgan ("overweight") says "more broadly on the story, we see ABBV as well-positioned with no major LOEs (loss of exclusivity) until the mid 2030s, ongoing upside from Skyrizi/Rinvoq, and balance sheet capacity for additional BD to address growth in the 2030s"
** Morgan Stanley ("overweight", PT: $239) says the long-term outlook for its newer immunology drugs, Skyrizi and Rinvoq, continues to bolster confidence in ABBV's long-term growth profile
** Truist Securities ("buy", PT: $217) says "ABBV continues to deliver strong growth into the longer-term and sees no other LOE for the rest of the decade, we see a clear growth trajectory into 2029"
** Morningstar (fair value: $184) says ABBV's transition to more effective immunology products in the face of Humira sales erosion demonstrates its strong competitive advantage
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。